Evolution of the Average Target: XP Inc.

Evolution of the Average Target - XP Inc.

Evolution of the Target Price: XP Inc.

Evolution of the Target Price - XP Inc.

Changes in Analyst Recommendations: XP Inc.

072052f2bd2f4e7f784c637c3507e._Nf1dE9zHS5CNFRJCZUUYha1pdaDyKBoB1fdpMmgCaY.z7WgPwVeJW1yfiE9XqVMDF7U7-Dkg5Q8SGK6l43yes-F4aM7CwosHChxAQ~5a6005884498dcf62b5eef0c64d1f5b6
10-08 UBS Adjusts Price Target on XP to $37 From $25, Keeps Buy Rating MT
10-06 XP Shares Rise After Itau BBA Upgrade MT
10-06 Itau BBA Upgrades XP to Outperform From Market Perform, Adjusts Price Target to $27 From $19 MT
08-31 Itau BBA Upgrades XP to Outperform From Market Perform, Adjusts PT to $22 From $19 MT
04-02 UBS Adjusts Price Target on XP to $28 From $25, Maintains Buy Rating MT
01-20 Jefferies Initiates XP at Buy With $22 Price Target MT
12-16 UBS Adjusts XP Price Target to $25 From $23, Maintains Buy Rating MT
16/10/25 UBS Adjusts Price Target on XP to $23 From $24, Maintains Buy Rating MT
23/06/25 XP Shares Drop After Downgrade From Itau BBA MT
23/06/25 Itau BBA Downgrades XP to Market Perform From Outperform, Adjusts Price Target to $21 From $20 MT
10/06/25 UBS Adjusts XP Price Target to $24 From $17, Maintains Buy Rating MT
04/06/25 Goldman Sachs Upgrades XP to Buy From Neutral, $23 Price Target MT
13/05/25 XP Shares Rise After Morgan Stanley Upgrades to Overweight From Equalweight MT
13/05/25 Morgan Stanley Upgrades XP to Overweight From Equalweight, Adjusts Price Target to $24 From $18 MT
07/04/25 UBS Adjusts Price Target on XP to $17 From $16, Keeps Buy Rating MT
18/03/25 Itau BBA Initiates XP at Outperform With $20 Price Target MT
24/01/25 XP Shares Rise After Upgrade From UBS MT
24/01/25 UBS Upgrades XP to Buy From Neutral, Cuts Price Target to $16 From $19 MT
10/12/24 BofA Securities Downgrades XP to Neutral From Buy, Price Target is $16 MT
25/11/24 UBS Cuts Price Target on XP to $19 From $21, Maintains Neutral Rating MT
11/07/24 UBS Downgrades XP to Neutral From Buy, Cuts Price Target to $21 From $30 MT
05/07/24 Bradesco BBI Downgrades XP to Neutral From Outperform, Cuts Price Target to $19 From $31 MT
05/06/24 Citigroup Adjusts Price Target on XP to $27 From $29, Maintains Buy Rating MT
30/04/24 XP Shares Decline After Goldman Sachs Downgrade MT
30/04/24 Goldman Sachs Downgrades XP to Neutral From Buy, Cuts Price Target to $23 From $30 MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
-16.41%
+16.9%
+19.41%
+17.39%
+27.2%
-15.05%
+46.67%
+46.99%
+47.74%
+19.71%
Average +21.05%
Weighted average by Cap. +20.01%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
160.50BRL
Average target price
134.90BRL
Spread / Average Target
-15.95%
High Price Target
189.57BRL
Spread / Highest target
+18.11%
Low Price Target
103.67BRL
Spread / Lowest Target
-35.41%

Analyst Consensus Detail

Analyst consensus - XP Inc.

Consensus revision (last 18 months)

Consensus revision (last 18 months) - XP Inc.
Trader
Investor
Global
Quality
ESG MSCI
AA
Ratings Surperformance© - XP Inc.